Stroud Sarah G, Passfall Lara, Alam Juhayer S, Segreto Frank A, Baum Rachel, Shah Neil V, Monsef Jad Bou, Paulino Carl B, Diebo Bassel G
Department of Orthopaedic Surgery, University of California, San Francisco, San Francisco, CA, 94143, USA.
Department of Orthopaedic Surgery and Rehabilitation Medicine, State University of New York (SUNY) Downstate Health Sciences University, Brooklyn, NY, 11203, USA.
Curr Rev Musculoskelet Med. 2025 Jun 5. doi: 10.1007/s12178-025-09983-6.
The purpose of this review was to critically appraise the literature and establish an evidence-based clinical guideline for the use of non-steroidal anti-inflammatory drugs (NSAIDs) in a fracture setting.
With few exceptions, studies in animals suggest that NSAIDs impair fracture healing. It is unclear if nonselective or cyclooxygenase-(COX)2-selective NSAIDs pose differing effects on fracture healing. Human studies show NSAID use to be a consistent risk factor for fracture non-union in skeletally mature populations across the literature and indicates that indomethacin in particular poses a significant risk for non-union of adult acetabular fractures. Current evidence appears to suggest no harm in using ketorolac or ibuprofen in a pediatric fracture population, while indomethacin poses a significant risk for non-union in adult acetabular fracture patients when used for six weeks. Despite the majority of available clinical studies showing NSAID use as a recurring risk factor for fracture non-union in adult populations, a lack of standardization amongst studies makes it difficult to determine any clinical recommendations about timing, dosage, duration, or type of agent administered. More high-quality prospective studies are needed.
本综述旨在严格评估文献,并制定基于证据的关于在骨折情况下使用非甾体抗炎药(NSAIDs)的临床指南。
除少数例外,动物研究表明NSAIDs会损害骨折愈合。尚不清楚非选择性或环氧化酶(COX)-2选择性NSAIDs对骨折愈合是否有不同影响。人体研究表明,在整个文献中,NSAIDs的使用是骨骼成熟人群骨折不愈合的一致危险因素,并且表明吲哚美辛尤其会对成人髋臼骨折的不愈合构成重大风险。目前的证据似乎表明,在儿童骨折人群中使用酮咯酸或布洛芬没有危害,而吲哚美辛在用于成人髋臼骨折患者六周时会对骨折不愈合构成重大风险。尽管大多数现有临床研究表明NSAIDs的使用是成人人群骨折不愈合的反复出现的危险因素,但研究之间缺乏标准化使得难以确定关于给药时间、剂量、持续时间或药物类型的任何临床建议。需要更多高质量的前瞻性研究。